Skip to main content

Table 3 Estimated number of IgG-treated patients with PID and SID in Canada by province

From: Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada

Province

2012 population (Thousands)

PID

SID

PID/SID combined

Alberta

3,873.7

396.1

213.3

609.3

British Columbia

4,622.6

472.6

254.5

727.1

Quebec

8,054.8

823.6

443.5

1,267.1

Manitoba

1,267.0

129.5

69.8

199.3

New Brunswick

756.0

77.3

41.6

118.9

Newfoundland & Labrador

512.7

52.4

28.2

80.7

Nova Scotia

948.7

97.0

52.2

149.2

Ontario

13,505.9

1,380.9

743.6

2,124.5

Prince Edward Island

146.1

14.9

8.0

23.0

Saskatchewan

1,080.0

110.4

59.5

169.9

Territories

113.1

11.6

6.2

17.8

Total

34,880.6

3,566.0

1,920.0

5,486.0